RadNet Acquires AI Ultrasound Innovator See-Mode, Boosting Diagnostic Imaging Capabilities

RadNet's Strategic Acquisition of See-Mode Technologies

RadNet, Inc. (NASDAQ:RDNT), a leading diagnostic imaging service provider, has completed the acquisition of See-Mode Technologies, an artificial intelligence (AI) innovator specializing in ultrasound imaging 1

1

. This strategic move aims to enhance RadNet's AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast imaging, integrating See-Mode's technology into RadNet's DeepHealth population health solutions 2

2

.

Enhancing Diagnostic Capabilities and Efficiency

See-Mode's AI applications for thyroid and breast ultrasound have already shown promising results. The thyroid ultrasound solution, which has received FDA approval, has been deployed across select RadNet imaging centers, demonstrating up to a 30% reduction in scan time 2

2

. This efficiency increase is expected to significantly enhance RadNet's capacity to provide better access and potentially increase revenue across its network of over 900 ultrasound units.

Dr. Howard Berger, RadNet's CEO, emphasized the importance of this acquisition, stating:

"Given the prevalence of thyroid and breast cancers, we believe AI has the potential to dramatically improve care in these areas." 2

2

Integration and Future Prospects

The integration of See-Mode's technology is anticipated to expand efficiencies to breast screenings and other clinical areas within RadNet's two million annual ultrasound studies 2

2

. This collaboration is set to bolster DeepHealth's leadership in population health solutions and will be offered to third parties as part of their commercialization efforts.

Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, expressed enthusiasm for the opportunity:

"We are excited to build the future of ultrasound on the platform provided by the combined expertise and data access of RadNet and DeepHealth." 2

2

Financial Implications and Market Position

RadNet's acquisition of See-Mode Technologies comes at a time when the company has demonstrated strong revenue growth of 12.76% over the last twelve months 2

2

. With a market capitalization of $4.27 billion, RadNet is positioning itself at the forefront of AI innovation in ultrasound imaging.

In its recent Q1 2025 earnings report, RadNet showcased a revenue increase to $471.4 million, surpassing forecasts of $446.21 million 2

2

. The company's digital health segment saw a significant 31.1% year-over-year increase, contributing to the overall growth 2

2

.

Analyst Perspectives and Future Outlook

Financial analysts have responded positively to RadNet's recent moves. Truist Securities maintained a Buy rating on RadNet, with a price target of $74, citing strong core growth and potential in the digital health sector 2

2

. Raymond James raised its price target for RadNet to $66, noting that the company's revenue and adjusted EBITDA performance exceeded expectations 2

2

.

RadNet has also raised its 2025 revenue and adjusted EBITDA guidance, reflecting optimism about future performance 2

2

. The company's strategic acquisitions, including the recent purchase of iCAD, a provider of advanced cancer detection and therapy solutions, further strengthen its AI capabilities in breast health solutions 2

2

.

As RadNet continues to invest in AI technology and expand its diagnostic imaging services, the company appears well-positioned to capitalize on the growing demand for advanced medical imaging solutions powered by artificial intelligence.